What's new — Rheumatoid arthritis¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 0 |
| last 3 months | 2 |
| last 6 months | 4 |
| last year | 10 |
| older than a year | 241 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-07-02 | Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial — Lancet Rheumatol ([PMID 42392130](https://pubmed.ncbi.nlm.nih.gov/42392130/){target="_blank" rel="noopener"}) | clinical-trials-landscape, overview, preclinical-autoimmunity-and-prevention |
| 2026-07-01 | 2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management — Int J Rheum Dis ([PMID 42362943](https://pubmed.ncbi.nlm.nih.gov/42362943/){target="_blank" rel="noopener"}) | guidelines |
| 2026-04-01 | Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): An Official 2025 ALAT Clinical Practice Guideline — Arch Bronconeumol ([PMID 42034552](https://pubmed.ncbi.nlm.nih.gov/42034552/){target="_blank" rel="noopener"}) | guidelines |
| 2026-04-01 | Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis — Ann Rheum Dis ([PMID 41997804](https://pubmed.ncbi.nlm.nih.gov/41997804/){target="_blank" rel="noopener"}) | guidelines |
| 2026-03-01 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update — Ann Rheum Dis ([PMID 41826212](https://pubmed.ncbi.nlm.nih.gov/41826212/){target="_blank" rel="noopener"}) | guidelines |
| 2026-03-01 | A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis — Arthritis Rheumatol ([PMID 40884017](https://pubmed.ncbi.nlm.nih.gov/40884017/){target="_blank" rel="noopener"}) | clinical-trials-landscape, preclinical-autoimmunity-and-prevention |
| 2026-01-02 | Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial — Lancet Rheumatol ([PMID 41576971](https://pubmed.ncbi.nlm.nih.gov/41576971/){target="_blank" rel="noopener"}) | clinical-trials-landscape, overview, preclinical-autoimmunity-and-prevention |
| 2025-12-02 | Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial — Nat Med ([PMID 41429981](https://pubmed.ncbi.nlm.nih.gov/41429981/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2025-11-03 | Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence — Ann Rheum Dis ([PMID 41188120](https://pubmed.ncbi.nlm.nih.gov/41188120/){target="_blank" rel="noopener"}) | difficult-to-treat-and-refractory-ra |
| 2025-11-02 | Rheumatoid arthritis-associated interstitial lung disease: clinical predictive model and external validation — Respir Res ([PMID 41299487](https://pubmed.ncbi.nlm.nih.gov/41299487/){target="_blank" rel="noopener"}) | extra-articular-and-comorbid-disease, ra-associated-interstitial-lung-disease, red-flags-and-safety-concerns |
Trials — what has moved¶
31 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 3 |
| trial records updated in the last month | 9 |
| trial records updated in the last 2 months | 10 |
| trial records updated in the last 3 months | 10 |
| trial records updated in the last 6 months | 11 |
| trial records updated in the last year | 14 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2025-01-08 | Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Ex | PHASE2 | 20 | Correlation Between Joint-specific Tilmanocept Uptake and CD206 Expres | 1 | 12 | 0 |
| 2023-11-21 | Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthri | PHASE2 | 144 | Number of Participants Who Developed Clinically-Apparent Rheumatoid Ar | 10 | 56 | 1 |
| 2021-08-17 | Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibit | PHASE4 | 4372 | Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin | 1132 | 3291 | 153 |
| 2014-04-08 | Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab | PHASE3 | 12 | Percent Change From Baseline in Synovial TNFa, CXCL13, IL-8, IL-6, IL- | 0 | 3 | 0 |
| 2010-03-23 | Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE | PHASE2 | 24 | American College of Rheumatology (ACR) 20 at Week 12 | 2 | 21 | 0 |
| 2009-11-19 | Study of Abatacept Versus Placebo to Assess the Prevention of Rheumato | PHASE2 | 56 | Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) b | 2 | 29 | 0 |
14 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| clinical-trials-landscape | 2026-07-02 | 4 | 36 |
| overview | 2026-07-02 | 2 | 38 |
| preclinical-autoimmunity-and-prevention | 2026-07-02 | 3 | 39 |
| guidelines | 2026-07-01 | 4 | 42 |
| difficult-to-treat-and-refractory-ra | 2025-11-03 | 1 | 37 |
| extra-articular-and-comorbid-disease | 2025-11-02 | 1 | 38 |
| ra-associated-interstitial-lung-disease | 2025-11-02 | 1 | 36 |
| red-flags-and-safety-concerns | 2025-11-02 | 1 | 35 |
| genetics-environment-and-mucosal-origins | 2025-08-01 | 0 | 38 |
| biomarkers-and-tissue-precision | 2025-07-02 | 0 | 41 |
| synovial-immunobiology | 2025-07-02 | 0 | 36 |
| patient-experience-and-advocacy | 2025-05-01 | 0 | 39 |
| conventional-dmards | 2025-04-08 | 0 | 37 |
| treat-to-target-and-remission | 2025-04-08 | 0 | 36 |
| biologic-dmards | 2024-09-01 | 0 | 37 |
| jak-inhibitors-and-targeted-therapy | 2024-09-01 | 0 | 36 |
| classification-and-diagnosis | 2024-06-02 | 0 | 38 |
| epidemiology-and-burden | 2024-06-02 | 0 | 38 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.